An estimated $60 billion worth of biotechnology drugs will lose patent protection next year and the Food and Drug Administration and the government’s top consumer watchdog agency can’t seem to agree on what to name cheaper, copycat versions. That could complicate efforts to hold down medical spending.
Learn more about your ad choices. Visit megaphone.fm/adchoices
